Major Depressive Disorder Clinical Trial
Official title:
Imaging-guided tDCS Therapy in Major Depression
Noninvasive transcranial direct current stimulation (tDCS) is a low-intensity neuromodulation
technique of minimal risk that has been used as an experimental procedure for reducing
depressive symptoms and symptoms of other brain disorders. Though tDCS applied to prefrontal
brain areas is shown to reduce symptoms in some people with major depressive disorder (MDD),
the extent of antidepressant response often differs. Methods that map current flow directly
in the brain while a person is receiving tDCS and that determine how functional neuroimaging
signal changes after a series of tDCS sessions may help us understand how tDCS works, how it
can be optimized, and if it can be used as an effective intervention for reducing depressive
symptoms. We will investigate these questions in a two-part randomized double blind
exploratory clinical trial. The first part of the trial will compare how current flow and
functional imaging signal differs in the brain when using tDCS with more focal stimulation,
called high definition (HD) tDCS, compared to conventional tDCS (C-tDCS) or sham (non-active)
tDCS in patients with MDD.
Sixty people with depression (20 in each group) will be randomized to receive either HD-tDCS,
C-tDCS or sham-tDCS for a total of 12 sessions each lasting 20 minutes occurring on
consecutive weekdays. At the first and last session, subjects will receive 20-30 minutes of
active or sham tDCS in the MRI scanner, which will allow us to map tDCS currents, and track
changes in regional cerebral blood flow (rCBF) pre-to- post treatment using completely
non-invasive methods. At the first and last session and mid-way through the trial,
participants will also complete a series of clinical ratings and neurocognitive tests
Transcranial direct current stimulation (tDCS), a noninvasive neuromodulation technique,
applied to the left dorsolateral prefrontal cortex (DLPFC) can reduce depressive symptoms and
improve cognitive control in major depressive disorder (MDD). Such findings suggest
modulation of top down prefrontal-limbic circuits, which are functionally distinct from
ventro-limbic networks and include reciprocally connected DLPFC and dorsomedial anterior
cingulate cortex (dACC). However, substantial variation in tDCS response is observed in MDD.
This may be due to imprecise stimulation protocols and suboptimal engagement of the neural
circuits mediating antidepressant response. Methods that optimize electrode placement and
account for individual variation in anatomy and that map current flow directly in the brain
may inform the mechanisms and potential clinical utility of tDCS. A new tDCS technique, high
definition (HD) tDCS, offers more focal stimulation than conventional tDCS (C-tDCS). The
degree to which C-tDCS or HD-tDCS engage dorsal prefrontal-limbic neural circuits is unknown,
yet is vital for understanding, confirming and subsequently improving possible therapeutic
effects. Innovative MRI techniques that are able to map tDCS currents in vivo and that track
changes in regional cerebral blood flow occurring with tDCS over time can provide direct
evidence of neural effects. Based on a) theoretical modeling of tDCS current flow, b) studies
showing hypo-metabolism, decreased CBF or activity in dorsal prefrontal-limbic networks, c)
modulation of these regions with treatment, and, c) our prior results showing significant
relationships in between change in dACC rCBF and clinical response to electroconvulsive
therapy (ECT), an established brain stimulation treatment, we will test for the tDCS
engagement and modulation of the DLPFC and dACC using tDCS current mapping performed in vivo
and perfusion MRI. MRI-guided neuronavigation will be used to optimize and standardize
electrode placement for DLPFC stimulation.
In this trial we will test for the target engagement of the DLPFC and dACC by comparing
C-tDCS, HD-tDCS and sham tDCS applied to the left DLPFC in patients with moderate to severe
MDD before and after they complete 12 daily 20-minute sessions of C-tDCS, HD-tDCS or Sham
tDCS (n=20 randomized to each group). In-vivo electric current mapping performed at different
current intensities (0-2 mA) for 20-30 minutes, and change in regional cerebral blood flow
(rCBF) measured before and after a 12-day tDCS trial will determine acute and longer-term
modulation of DLPFC and dACC circuitry for each tDCS modality respectively.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05537558 -
Precision Medicine for the Prediction of Treatment (PROMPT) Response (PROMPT)
|
||
Terminated |
NCT02192099 -
Open Label Extension for GLYX13-C-202, NCT01684163
|
Phase 2 | |
Completed |
NCT03142919 -
Lipopolysaccharide (LPS) Challenge in Depression
|
Phase 2 | |
Recruiting |
NCT05547035 -
Identification of Physiological Data by a Wearable Monitor in Subjects Suffering From Major Depression Disorders
|
N/A | |
Terminated |
NCT02940769 -
Neurobiological Effects of Light on MDD
|
N/A | |
Recruiting |
NCT05892744 -
Establishing Multimodal Brain Biomarkers for Treatment Selection in Depression
|
Phase 4 | |
Recruiting |
NCT05537584 -
SMART Trial to Predict Anhedonia Response to Antidepressant Treatment
|
Phase 4 | |
Active, not recruiting |
NCT05061706 -
Multicenter Study of Lumateperone as Adjunctive Therapy in the Treatment of Patients With Major Depressive Disorder
|
Phase 3 | |
Completed |
NCT04479852 -
A Study of the Safety and Efficacy of SP-624 in the Treatment of Adults With Major Depressive Disorder
|
Phase 2 | |
Recruiting |
NCT04032301 -
Repeated Ketamine Infusions for Comorbid PTSD and MDD in Veterans
|
Phase 1 | |
Recruiting |
NCT05527951 -
Enhanced Measurement-Based Care Effectiveness for Depression (EMBED) Study
|
N/A | |
Completed |
NCT03511599 -
Cycloserine rTMS Plasticity Augmentation in Depression
|
Phase 1 | |
Recruiting |
NCT04392947 -
Treatment of Major Depressive Disorder With Bilateral Theta Burst Stimulation
|
N/A | |
Recruiting |
NCT05895747 -
5-HTP and Creatine for Depression R33 Phase
|
Phase 2 | |
Recruiting |
NCT05273996 -
Predictors of Cognitive Outcomes in Geriatric Depression
|
Phase 4 | |
Recruiting |
NCT05813093 -
Interleaved TMS-fMRI in Ultra-treatment Resistant Depression
|
N/A | |
Recruiting |
NCT05135897 -
The Neurobiological Fundaments of Depression and Its Relief Through Neurostimulation Treatments
|
||
Enrolling by invitation |
NCT04509102 -
Psychostimulant Augmentation of Repetitive TMS for the Treatment of Major Depressive Disorder
|
Early Phase 1 | |
Recruiting |
NCT06145594 -
EMA-Guided Maintenance TMS for Depression
|
N/A | |
Recruiting |
NCT06026917 -
Assessing Dopamine Transporter Occupancy in the Patients With Depression Brain With Toludesvenlafaxine Hydrochloride Extended-Release Tablets Using 11C-CFT Positron Emission Tomography (PET)
|
Phase 4 |